Valganciclovir for symptomatic congenital cytomegalovirus disease.
AUTHORS
Kimberlin
DW ,
Jester
PM ,
Sánchez
PJ ,
Ahmed
A ,
Arav-Boger
R ,
Michaels
MG ,
Ashouri
N ,
Englund
JA ,
Estrada
B ,
Jacobs
RF ,
Romero
JR ,
Sood
SK ,
Whitworth
MS ,
Abzug
MJ ,
Caserta
MT ,
Fowler
S ,
Lujan-Zilbermann
J ,
Storch
GA ,
DeBiasi
RL ,
Han
JY ,
Palmer
A ,
Weiner
LB ,
Bocchini
JA ,
Dennehy
PH ,
Finn
A ,
Griffiths
PD ,
Luck
S ,
Gutierrez
K ,
Halasa
N ,
Homans
J ,
Shane
AL ,
Sharland
M ,
Simonsen
K ,
Vanchiere
JA ,
Woods
CR ,
Sabo
DL ,
Aban
I ,
Kuo
H ,
James
SH ,
Prichard
MN ,
Griffin
J ,
Giles
D ,
Acosta
EP ,
Whitley
RJ ,
,
. The New England journal of medicine. 2015 3 5; 372(10). 933-43
- PMID: 25738669 [PubMed].
ABSTRACT
The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time.
The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time.
Tags: Alumni Publications 2015